RecruitingNCT06778512

LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer

LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Enrollment

2,500 participants

Start Date

Jun 1, 2019

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Cancer NSCLC Lung

Summary

This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood and tissue samples from patients with lung nodules to study proteins (proteomics) over time. The goal is to build a detailed database that could help researchers understand which lung nodules are benign versus cancerous, and ultimately improve how lung cancer is detected and managed. **You may be eligible if...** - You are between 18 and 75 years old - You have been found to have a lung nodule on a CT scan - You are having surgery and have completed lung function tests beforehand - Your preoperative CT scan is of good quality and was done within one month of your lung function test **You may NOT be eligible if...** - Your lung function testing is incomplete or of poor quality - Your CT scan has significant image quality problems - The gap between your lung function test and CT scan is more than one month - You have severe pre-existing respiratory conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERUsing tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t

Peripheral blood samples from enrolled participants will be drawn, or lesion tissues will be obtained through procedures such as biopsy or surgery, followed by quantitative proteomics analysis using mass spectrometry.